pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer
American Society of Clinical Oncology
Precision Medicine Group joins McKesson's Oncology & Multispecialty segment. Read more in McKesson Business Highlights.